A Placebo-controlled, Double-blind, Randomized Trial of a Single Intra-articular Delivery of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee

Trial Profile

A Placebo-controlled, Double-blind, Randomized Trial of a Single Intra-articular Delivery of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs SB 061 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MODIFY2
  • Sponsors Symic OA
  • Most Recent Events

    • 23 Aug 2017 According to a SYMIC Biomedical media release, the company expects to report top-line data from the study in early 2018.
    • 23 Aug 2017 According to a SYMIC Biomedical media release, first patient has been enrolled in the study.
    • 23 Aug 2017 Status changed from not yet recruiting to recruiting, according to a SYMIC Biomedical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top